Page 8 - Serum Institute Of India

Production of 1.35 bn vaccine doses between August, December a long haul

Covishield production to cross 120 mn doses a month, Covaxin 58 mn doses a month

Serum Institute may start Covid-19 vaccine trials on kids in August

SII will conduct trials on those aged between two to 17 years

Covid-19 pandemic: SII partners CII in push to vaccinate rural areas

SII will be working with the CII, which has set up vaccination camps in smaller towns and rural areas

Expert panel recommends trials on mixing Covaxin and Covishield

As per sources, the application of the interchangeability study protocol of Covishield and Covaxin was moved by Christian Medical College (CMC) in Vellore.

Govt recommends nod to SII for phase 2/3 trials of Covovax on children

An expert panel of India's Central Drug Authority recommended granting permission to Serum Institute of India for conducting phase 2/3 trials of Covid vaccine Covovax on children aged 2 to 17 years

Expert panel recommends nod to SII for phase 2/3 trials of Covovax for 2-17

The trials would cover 920 children, 460 each in the age-group of 12-17 and 2-11 across 10 sites.

Covishield at Delhi govt vaccine centres reserved for 2nd dose till Jul31

Delhi government issued an order to reserve Covishield shots only for beneficiaries whose second dose is due, across all its vaccination centres till July 31.

SII writes to Mandaviya proposing reforms in drug regulatory system

Serum Institute of India (SII) has written to Union Health Minister Mansukh Mandaviya suggesting reforms in the existing drug regulatory system

What is the controversy surrounding Serum Institute's Covishield and EMA?

The vaccine did not make it to the European regulator's approved list, although it has been approved by WHO and also the UK MHRA

New price good, but Rs 250 a dose better: Covid-19 vaccine makers

Centre has ordered 660 mn doses, expected to be supplied between Aug & Dec

No application received for EU authorisation of Covishield: Drug regulator

The European Medicines Agency (EMA) hasn't got any application to authorise Covishield, the vaccine made by the Serum Institute of India

Small contract manufacturers wait to take a shot at Covid vaccines

A host of lesser-known vaccine makers are eyeing contract manufacturing opportunities for global and domestic majors

Serum Institute partners with RDIF to make 300 mn doses of Sputnik V

RDIF says SII can make combination doses of Astra-Sputnik in future

Serum Institute to start manufacturing Sputnik vaccine in September

Serum Institute of India (SII) will start production of Sputnik vaccine at the company's facilities in September, Russian Direct Investment Fund (RDIF) said on Tuesday

Covishield vaccine out of stock at Pune vaccination centres amid shortage

Amid a shortage of Covid-19 vaccines in state, the Pune mayor on Sunday said that the Covishield will not be available at any vaccination centre under jurisdiction of Pune Municipal Corporation today

Top headlines: Indian SPACs to raise $1 bn, SII to double vax production

Business Standard brings you the top headlines on Monday

Serum Institute may double production of AstraZeneca-Oxford vaccine in 2022

Expect 200-million AstraZeneca vaccine doses next year

Covovax denied trials on children; no nod needed for Sputnik Light

The decision comes as a setback to SII, which had sought permission to start a pediatric clinical trial of Covovax

Govt panel recommends against SII testing Covovax on 2-17 age group: Report

"The Subject Expert Committee on Covid-19 of Central Drugs Standard Control Organisation, which deliberated on the application, noted that vaccine has not been approved in any country", a source said

Serum Institute applies for EU nod through drugmaker AstraZeneca

SII Chief Executive Officer Adar Poonawalla said on Mon­day he had taken it up at the "highest levels".